Sahana System Limited is launching a Rights Issue worth Rs 48.87 crore, available for subscription from 11 October 2024 to 25 October 2024. Shareholders will be entitled to 1 Rights equity share for every 15 fully paid-up equity shares they own as of the record date, 25 September 2024. Each share has a face value of Rs. 10, and the issue price is set at Rs. 890 per share.
Stay tuned with us for comprehensive details on the Sahana System Ltd 2024 Rights Issue, including the issue size, entitlement, payment terms, and more.
Corporate Action | |
---|---|
Security Name | Sahana System Ltd |
Issue Open/Close | October 11, 2024 - October 25, 2024 |
Record Date | September 25, 2024 |
Issue Size (Amount) | ₹48.87 Crores |
Issue Size (Shares) | ₹549,084 |
Right Issue Price | ₹890 per share |
Face Value | ₹10 per share |
CMP | ₹1334 |
Renunciation of Rights Entitlements | October 16, 2024 |
Terms of Payment | The entire amount of ₹890 per Rights Equity Share is payable at the time of application. |
Entitlement | 1 Rights Equity Share for every 15 fully paid-up Equity Shares held on the Record Date. |
Disclaimer: The Information compiled by CEBPL on a best efforts basis from information CEBPL received from third party vendors, believed to be reliable. The information may contain errors or omissions; and is subject to change without prior or additional notice. CEBPL provides corporate action information that may be of interest or relevance to CEBPL clients. This does not constitute a recommendation or advice by CEBPL, and CEBPL Clients may not rely upon it. CEBPL does not warrant that the information provided is accurate, timely, or complete. CEBPL Clients are urged to verify the information prior to using it in their investing and trading decisions, including, but not limited to, referral to independent financial news resources, company announcements, and regulatory filings or disclosures. "Investment in securities market are subject to market risks, read all the related documents carefully before investing". Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of retums to investors.
Name of Compliance Officer - Prashant Salian
Email Id - prashant.salian@choiceindia.com
Contact no. 022-67079999, Ext - 2310
Name of Grievance Officer - Deepika Singhvi
Email Id - ig@choiceindia.com
Contact no. 022-67079999. Ext-834.
Invest in best pharma mutual funds in India for 2020 with Investica. Explore our top recommended pharma mutual funds to start investing today.